Price T Rowe Associates Inc. MD Raises Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Price T Rowe Associates Inc. MD lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 148.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,049,388 shares of the company's stock after buying an additional 1,223,957 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.18% of Teva Pharmaceutical Industries worth $45,170,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Oarsman Capital Inc. acquired a new position in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $29,000. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter worth $50,000. Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at about $66,000. IFP Advisors Inc raised its stake in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Down 0.8 %

Shares of TEVA traded down $0.14 during trading on Monday, reaching $16.06. 5,271,660 shares of the company traded hands, compared to its average volume of 12,179,191. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a market cap of $18.20 billion, a PE ratio of -11.07, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The stock has a 50-day simple moving average of $15.11 and a 200-day simple moving average of $17.49. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80.

Analysts Set New Price Targets

Several analysts have commented on TEVA shares. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.